There are numerous factors that impact the larger picture in cardiology, especially from a business perspective. Here are several overarching trends effecting cardiology in 2019 and beyond. 
 
Cardiology Cost Drivers

The scientific journal Nature recently published an article from Munich University Hospital which describes the long-term survival of baboons that had received a heart transplant from genetically modified pigs.1 This is an important step forward on the way to being able to give humans porcine heart transplants.

December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all lots of products containing Valsartan within expiry due to an impurity that has been classified as a probable human carcinogen. Valsartan is used for the treatment of high blood pressure for the treatment of heart failure, and to reduce cardiovascular mortality following myocardial infarction.

December 10, 2018 — Electrophysiology, while currently a relatively small market at $4.6 billion in 2018, has recently become of great interest in the medical devices field, with the market expected to reach $8.5 billion by 2023, according to GlobalData. This would represent a compound annual growth rate (CAGR) of 4.6 percent.

Medical artificial intelligence (AI) company Bay Labs announced a collaboration with Edwards Lifesciences focused on improving the detection of heart disease. The partnership involves multiple initiatives, including the development of new AI-powered algorithms in Bay Labs’ EchoMD measurement and interpretation software suite, the integration of EchoMD algorithms into Edwards Lifesciences’ CardioCare quality care navigation platform, and support for ongoing clinical studies at leading institutions.

30th Anniversary of the Great Wall International Congress of Cardiology

American Heart Association Scientific Sessions (AHA)

Hitachi Medical Systems Europe introduced what it calls the next level of intelligent Vector Flow Mapping (iVFM) at EuroEcho Imaging 2018, Dec. 5-8 in Milan, Italy.

New data from the Phase 3 CASSINI study showed a 60 percent reduction of venous thromboembolism (VTE, or blood clot) events with oral anticoagulant Xarelto (rivaroxaban) compared to placebo in high-risk patients with cancer. The composite primary endpoint of VTE occurrence did not reach statistical significance during the full study period. Bleeding rates were low, though higher with Xarelto.

Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6, 2018, against GE Healthcare for theft and misappropriation of Spectrum Dynamics' trade secrets and intellectual property. The lawsuit was filed in the U.S. District Court for the Southern District of New York.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now